MiMedx Group, Inc.
Every calculator, already run for MDXG
Open the full toolkit →You have the numbers on MDXG. Get the argument.
A written report on which of these readings actually decide the outcome for MiMedx Group, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering MDXGAnalyst Price Target Disagreement for MiMedx Group, Inc.
Wall Street's bull case implies +68% from the current price; the bear case implies +26%. A 42% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MDXG
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About MiMedx Group, Inc.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protect…
MDXG — frequently asked
Is MDXG a buy right now?
Wall Street's consensus rating on MiMedx Group, Inc. is Strong Buy across 5 analysts, with a mean price target of $7.40 (+55% vs. the current $4.77). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is MDXG overvalued?
MDXG trades at 119.3x trailing earnings, against a DCF fair value of $4 per share. The current price implies 8% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is MDXG's next earnings date?
MiMedx Group, Inc. is next scheduled to report earnings around Oct 28, 2026. A full MDXG research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for MiMedx Group, Inc.?
Analysts covering MiMedx Group, Inc. (MDXG) range from a bear-case target of $6.00 to a bull-case high of $8.00, with a mean consensus target of $7.40 across 5 analysts. The spread of $2.00 (42% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare MiMedx Group, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For MiMedx Group, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MDXG research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on MiMedx Group, Inc., in minutes. 3 free reports included with every account — no credit card required.